This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor:—
Happily this report confirms the favorable results of Manchester (Ann Intern Med47: 1202, 1957) and of Bjerkelund (Acta Med Scand, suppl 330,1957). Although the Veterans Administration report makes reference to Bjerkelund's work, and to the Medical Research Council's report by its Working Party (Brit Med J1:803, 1959), reference to Manchester's contribution is omitted. The omission is noteworthy, especially when the Research Council's report observed that only the Manchester and Bjerkelund studies approached their ideal and were used for comparison with their investigations, which supported Manchester's findings that protection against subsequent infarction lasted several years.All of Manchester's patients were first seen during an episode of acute myocardial infarction. Alternate patients selected at random for control received a placebo of ascorbic acid, and the others received oral anticoagulants plus ascorbic acid. Otherwise, all conditions were identical for both groups, including visits and determinations of prothrombin
Rabkin B, Spring S. Long-Term Anticoagulants for Myocardial Infarction. JAMA. 1965;194(8):934. doi:10.1001/jama.1965.03090210097035
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: